RELAY THERAPEUTICS, INC. |
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
| 6.095 USD | -4.02% |
|
+0.82% | -44.05% |
| Mar. 12 | Transcript : Relay Therapeutics, Inc. Presents at Barclays 26th Annual Global Healthcare Conference 2024, Mar-12-2024 07:30 AM | |
| Feb. 23 | Relay Therapeutics Q4 Loss Widens, Reports No Revenue | MT |
Financials (USD)
| Sales 2024 * | 400K | Sales 2025 * | 10.8M | Capitalization | 840M |
|---|---|---|---|---|---|
| Net income 2024 * | -372M | Net income 2025 * | -387M | EV / Sales 2024 * | 1,634 x |
| Net cash position 2024 * | 187M | Net cash position 2025 * | 44.11M | EV / Sales 2025 * | 73.7 x |
| P/E ratio 2024 * |
-2.2
x | P/E ratio 2025 * |
-2.22
x | Employees | 323 |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 96.29% |
More Fundamentals
* Assessed data
More news
Latest transcript on Relay Therapeutics, Inc.
More recommendations
More press releases
| 1 day | -8.19% | ||
| 1 week | -3.44% | ||
| Current month | -28.92% | ||
| 1 month | -21.65% | ||
| 3 months | -40.10% | ||
| 6 months | -1.83% | ||
| Current year | -46.41% |
1 week
5.70
6.43
1 month
5.708.43
Current year
5.7012.14
1 year
5.7013.32
3 years
5.7038.61
5 years
5.7064.37
10 years
5.7064.37
| Managers | Title | Age | Since |
|---|---|---|---|
Sanjiv Patel
CEO | Chief Executive Officer | 50 | 17-02-28 |
Mark Murcko
FOU | Founder | 64 | 15-05-03 |
Alexis Borisy
FOU | Founder | 52 | 15-05-03 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Douglas Ingram
BRD | Director/Board Member | 61 | 19-05-31 |
Linda Hill
BRD | Director/Board Member | 67 | 18-10-08 |
Jami Rubin
BRD | Director/Board Member | 60 | 19-09-30 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 0.17% | 0 M€ | 0.00% | - | |
| 0.12% | 2 M€ | -.--% | ||
| 0.12% | 0 M€ | 0.00% | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-04-25 | 6.17 | -2.83% | 481 716 |
| 24-04-24 | 6.35 | +7.63% | 1,706,010 |
| 24-04-23 | 5.9 | -0.84% | 798,976 |
| 24-04-22 | 5.95 | -0.17% | 1,058,133 |
| 24-04-19 | 5.96 | -2.45% | 2,368,178 |
Delayed Quote Nasdaq, April 25, 2024 at 10:44 am EDT
More quotes
Relay Therapeutics Inc. is a clinical-stage precision medicine company. The Company is focused on enhancing small molecule therapeutic discovery in targeted oncology and genetic disease indications. The Companyâs Dynamo platform integrates an array of computational and experimental approaches designed to drug protein targets that have previously been intractable or inadequately addressed. The Companyâs lead product candidates, such as RLY-2608, Lirafugratinib (RLY-4008), and Migoprotafib (GDC-1971). RLY-2608 is an allosteric, pan-mutant and isoform-selective phosphoinostide 3 kinase alphas (PI3Kα), inhibitor. RLY-4008, is a potent, selective, and oral small molecule inhibitor of FGFR2, a receptor tyrosine kinase that is frequently altered in certain cancers. GDC-1971 is an inhibitor of Src homology region 2 domain-containing phosphatase-2 (SHP2), as a monotherapy in patients with advanced or metastatic solid tumors.
Calendar
2024-05-01
- Q1 2024 Earnings Release (Projected)
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
B-
Sell
Buy
Mean consensus
BUY
Number of Analysts
12
Last Close Price
6.35
USD
Average target price
23.05
USD
Spread / Average Target
+263.06%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -46.41% | 840M | |
| +0.80% | 43.84B | |
| +5.26% | 41.68B | |
| +45.38% | 41.25B | |
| -10.92% | 27.04B | |
| +7.25% | 25.53B | |
| -25.69% | 18.18B | |
| -4.40% | 12.29B | |
| +25.09% | 12.29B | |
| +6.82% | 11.15B |
- Stock Market
- Equities
- RLAY Stock
